Sherlock Biosciences announced today it appointed Bryan Dechairo as its president and CEO and he will join the company’s board.
Dechairo will succeed co-founder Rahul Dhanda, who will continue to serve as a board member until the end of 2021, after which he will assume the role of strategic adviser in 2022.
He joins Cambridge, Mass.-based Sherlock Biosciences after most recently holding the position of executive VP of clinical development at Myriad Genetics. He was chief medical officer, chief scientific officer and senior VP of R&D at Assurex Health, which Myriad acquired in 2016.
Before Assurex Health, Dechairo held leadership positions at Medco Health Solutions, Pfizer and other diagnostic and therapeutics companies, according to a news release.
“I’m thrilled to be joining Sherlock at such a pivotal moment for the company,” Dechairo said in the release. “The past year’s successes are a remarkable testament to the commitment of this team and the disruptive potential of the Sherlock and Inspectr platforms. I look forward to leveraging my experience in global diagnostic product commercialization to advance Sherlock’s mission to decentralize and democratize advanced molecular diagnostics, bringing easy, rapid and accurate diagnostic tests where and when they are needed most.”
The company develops applications of Sherlock, a CRISPR-based method for detecting and quantifying genetic sequences, and Inspectr, a synthetic biology-based, instrument-free molecular diagnostic platform. It was included in MassDevice’s 2020 list of medical device startups you need to know.
“After a year of unprecedented growth and acceleration of our CRISPR and synthetic biology technologies, Sherlock is poised to disrupt diagnostics through the launch of real-world solutions that provide accurate, actionable health information wherever and whenever it is needed,” Sherlock co-founder & board member Jim Collins said. “Bryan brings 20-plus years of experience spanning research to commercial, with a proven track record of funding and scaling business from venture-backed start-ups to profitable public companies. We feel confident that his vast experience, coupled with his passion for providing patient access to effective and cost-saving novel technologies, will lead us into the next chapter for Sherlock.”